Title |
α9-Nicotinic Acetylcholine Receptors Contribute to the Maintenance of Chronic Mechanical Hyperalgesia, but Not Thermal or Mechanical Allodynia
|
---|---|
Published in |
Molecular Pain, January 2014
|
DOI | 10.1186/1744-8069-10-64 |
Pubmed ID | |
Authors |
Sarasa Mohammadi, Macdonald J Christie |
Abstract |
The current pharmacological treatments for chronic pain are limited. The first analgesic drug approved for clinical use in decades that has a novel molecular target is the synthetic version of a naturally occurring conotoxin. Several conotoxins that target ion channels have progressed to clinical trials for the relief of pain. Vc1.1 and RgIA are analgesic α-conotoxins that target α9-subunit-containing nicotinic acetylcholine receptors (α9-nAChR) as well as GABAB receptor mechanisms. However, the evidence for the involvement of α9-nAChRs in pain is controversial. In the present study, the role of the α9-nAChR in pain was assessed using a battery of behavioural pain tests and pain models in α9-nAChR knockout (KO) mice. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 41 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 20% |
Student > Ph. D. Student | 6 | 15% |
Student > Master | 5 | 12% |
Researcher | 4 | 10% |
Student > Postgraduate | 2 | 5% |
Other | 6 | 15% |
Unknown | 10 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 7 | 17% |
Neuroscience | 7 | 17% |
Medicine and Dentistry | 6 | 15% |
Biochemistry, Genetics and Molecular Biology | 3 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Other | 5 | 12% |
Unknown | 10 | 24% |